A panel of pulmonologists discuss their use of CyPath® Lung in clinical practice as part of a comprehensive approach to lung cancer risk assessment, pulmonary nodule management, and surveillance of lung cancer survivors post-treatment. A key theme that emerges from the conversation is how CyPath® Lung enhances clinical confidence in determining appropriate next steps for patients at risk for lung cancer.

Moderator: Gordon Downie, MD, PhD bioAffinity Technologies Chief Medical Officer

Panelists:

·      Sai Karan Vamsi Guda, DO Interventional pulmonologist with Texas Pulmonary & Critical Care Consultants

·      Michael Nicholson, DO Pulmonologist and critical care specialist with RWJBarnabas Health Medical Group 

·      Gregory White, MD Pulmonologist at CHRISTUS Trinity Clinic